

Re-emergence of MK-7009 resistance associated Amino acid variants (RAVs) following retreatment of patients previously exposed to MK-7009



Richard Barnard, Julie Strizki, Carolyn McHale, William Newhard, Carol Cheney, Don Graham, Daria Hazuda, Christopher Gilbert, Michelle Treitel*

*Current address; Bristol Myers Squibb Princeton, NJ. Bristol Myers Squibb


Summary of Patient Dosing Details

Patient #	Genotype	First MK-7009 Treatment/Dose	Days Between Doses	Second MK-7009 Treatment
1	1b	MK-7009 300 mg b.i.d. + peg-IFN + RBV	316	MK-7009 600 mg b.i.d. + peg-IFN + RBV
2	1a	7-days MK-7009 125 mg q.d. monotherapy	908	MK-7009 600 mg b.i.d. + peg-IFN + RBV
3	1a	MK-7009 300 mg b.i.d. + peg-IFN + RBV	376	MK-7009 600 mg b.i.d. + peg-IFN + RBV
4	1a	7-days MK-7009 125 mg q.d. monotherapy	832	MK-7009 600 mg b.i.d. + peg-IFN + RBV


Patient 2; Infected with Genotype 1b virus




- wild-type
- R155K
- R155G
- V55A



- R155K
- V36E/R155K
- Y56H/R155K
- R155T





- wild-type
- V36A
- F43L
- F43S




- D168T
- F43L/D168T


Patient 4; Infected with Genotype 1a virus




■ wild-type
■ F43L



■ wild-type
■ R155K
■ V36M
■ F43L
■ V36A/R155K
■ R155K/A156T




■ wild-type
■ R155K
■ T54A
■ T54I
■ V55A
■ V55I




■ R155K
■ T54I/R155K
■ F154S/R155K
■ R155E

Patient 4: Phylogenetic Analysis



Closer View of Phylogenetic Tree



Time Point 4

Time Point 2

Time Point 4